期刊
CURRENT PHARMACEUTICAL DESIGN
卷 19, 期 18, 页码 3190-3200出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/13816128113199990338
关键词
Proteasome inhibitor; bortezomib; adverse effect; resistance
资金
- National Natural and Science Foundation of China [81071935]
- National Basic Research Program of China (Program 973) [2011CB933501, 2011CB933503]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据